NICE recommendations for GLP-1 therapy include: For type 2 diabetes (NICE NG28): GLP-1 therapy should only be continued if there is a beneficial metabolic response (HbA1c reduction of 11 mmol/mol [1.0%] and weight loss of 3% of initial body weight at 6 months)
Chiechio S, Copani A, Gereau RW 4th, Nicoletti F
Research shows high doses of glutathione administered intravenously can effectively reduce a marker of cell damage in nonalcoholic liver disease
Cost, Accessibility, and Legal Status The best NAD+ supplementation method depends not just on how well it works
About Mary Mary Barna Bridgeman, PharmD, BCPS, BCGP is a Clinical Professor at the Ernest Mario School of Pharmacy at Rutgers University
10.1016/j.ijscr.2024.109931 9 CaballeroM.LukawskaJ.LeeT.DuguP